Gregory Russotti Sells 5,000 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $3.10, for a total value of $15,500.00. Following the completion of the transaction, the insider now owns 297,319 shares of the company’s stock, valued at approximately $921,688.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Century Therapeutics Trading Up 6.4 %

Shares of NASDAQ:IPSC opened at $3.15 on Friday. The stock has a fifty day simple moving average of $4.07 and a two-hundred day simple moving average of $3.13. The stock has a market capitalization of $204.18 million, a price-to-earnings ratio of -1.38 and a beta of 1.33. Century Therapeutics, Inc. has a 12-month low of $1.28 and a 12-month high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.07. The business had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $1.69 million. Century Therapeutics had a negative return on equity of 54.73% and a negative net margin of 6,115.12%. As a group, equities research analysts predict that Century Therapeutics, Inc. will post -1.94 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Canaccord Genuity Group raised their target price on Century Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, March 15th. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Century Therapeutics in a research note on Friday, March 15th. Finally, Piper Sandler restated an “overweight” rating and issued a $9.00 target price (down previously from $10.00) on shares of Century Therapeutics in a research note on Friday, April 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.60.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Abel Hall LLC bought a new stake in shares of Century Therapeutics in the 4th quarter worth $33,000. Avidity Partners Management LP increased its holdings in shares of Century Therapeutics by 23.4% in the 4th quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock worth $4,499,000 after purchasing an additional 256,500 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of Century Therapeutics by 0.4% in the 4th quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock worth $2,053,000 after purchasing an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.